Opinion|Videos|January 10, 2025

Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine + rituximab (ECHO), acalabrutinib + lenalidomide + rituximab (ALR), acalabrutinib + umbralisib + ublituximab (AU2), ibrutinib + rituximab (ENRICH), and zanubrutinib + rituximab (CHESS), are exploring novel combinations to improve treatment outcomes and address unmet clinical needs in MCL therapy.

Video content above is prompted by the following:

  1. Provide an overview of the following emerging BTKi treatment regimens in treatment-naive patients with MCL.
  • Acalabrutinib + bendamustine + rituximab
  • Acalabrutinib + lenalidomide + rituximab
  • Acalabrutinib + umbralisib + ublituximab
  • Ibrutinib + rituximab
  • Zanubrutinib + rituximab

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo